Effect of Visual Retraining After Stroke
Launched by UNIVERSITY OF ROCHESTER · Oct 31, 2023
Trial Information
Current as of July 09, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- • Cortically Blind Subjects
- Inclusion:
- • Between 21 and 80 years of age
- • Residents of the United States or Canada
- • Unilateral stroke or stroke-like damage to primary visual cortex or its immediate afferent white matter sustained within the specified age range (21-75 years)
- • Reliable visual field defects in both eyes as measured by Humphrey, MAIA, Goldmann, and/or equivalent perimetry, large enough to enclose a 5-deg diameter visual stimulus.
- • Able to fixate on visual targets reliably for 1000ms
- • Must have a home computer (desktop or laptop) and reliable internet access
- • Willing, able, and competent to provide informed consent
- • Normal cognitive abilities, able to understand written and oral instructions in English, and competent and responsible adults in order to complete the visual training at home, independently, as instructed, for several months.
- Exclusion:
- • Past or present eye disease interfering with visual acuity
- • BCVA worse than 20/40 in either eye
- • Damage to the dorsal Lateral Geniculate Nucleus
- • Diffuse whole brain degenerative processes
- • History of traumatic brain injury
- • Any other brain damage deemed by study staff to potentially interfere with training ability or outcome measures
- • Documented history of drug/alcohol abuse
- • Currently taking neuroactive medications which would impact training, as determined by PI
- • Presence of cognitive or seizure disorders
- • One-sided attentional neglect
- • Subjects who lack the competence or are otherwise unable to perform the visual training exercises as directed.
- • Control Subjects (n = 50)
- Inclusion:
- • Between 21 and 80 years of age
- • Report no history of neurological disorder.
- • Competent and responsible, as determined by the Principal Investigator.
- Exclusion:
- • Presence of damage to the visual system
- • Presence of an active disease process involving their nervous system.
- • Cognitive or seizure disorders
- • Best corrected visual acuity worse than 20/40 in either eye
- • Presence of vision field loss from ocular disease or disorder
About University Of Rochester
The University of Rochester is a leading academic institution dedicated to advancing medical research and improving patient care through innovative clinical trials. Renowned for its commitment to excellence in education, research, and clinical practice, the university fosters a collaborative environment that integrates cutting-edge scientific inquiry with practical applications in healthcare. With a focus on diverse therapeutic areas, the University of Rochester aims to enhance treatment options and outcomes for patients while contributing to the broader scientific community through rigorous study design and ethical standards in clinical research.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Rochester, New York, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported